BAFNA PHARMACEUTICALS LTD
BAFNAPH · General/Diversified · NSE
₹136
Current Market Price
Fair Value (DCF)
₹33
Margin of Safety
-75.9%
Updated 1d ago
YieldIQ Score
17/100
Piotroski F-Score
3/9
Economic Moat
None
Confidence
19%
ROE
—
Debt/Equity
0.36
WACC
11.1%
Market Cap
₹322 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
6.6%
Return on capital employed
EV / EBITDA
21.7×
Enterprise multiple
Debt / EBITDA
1.7×
Leverage vs earnings
Interest Coverage
2.6×
EBIT covers interest
Current Ratio
1.63×
Short-term liquidity
Asset Turnover
0.95×
Revenue per ₹ of assets
Revenue CAGR (3Y)
19.7%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹136.02
Bear case
₹32.73
MoS -315.6%
Base case
₹32.73
MoS -315.6%
Bull case
₹52.02
MoS -161.5%
Ratio Trends
BAFNAPH · last 4 annual periods
ROE
4.9%
ROCE
10.3%
Operating Margin
—
Debt / Equity
0.33×
PE
57.4×
EV / EBITDA
27.7×
Historical Financials
BAFNAPH · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹71.2 Cr | ₹85.1 Cr | ₹115 Cr | ₹152 Cr | ₹146 Cr | +19.6% |
| EBITDA | — | ₹11.2 Cr | ₹18.7 Cr | ₹14.3 Cr | ₹11.6 Cr | +0.8% |
| EBIT | ₹6.6 Cr | ₹5.9 Cr | ₹13.7 Cr | ₹9.6 Cr | — | +10.1% |
| PAT | ₹5.8 Cr | ₹5.2 Cr | ₹11.3 Cr | ₹7.3 Cr | ₹4.2 Cr | -8.1% |
| EPS (diluted) | ₹2.46 | ₹2.17 | ₹4.86 | ₹3.11 | — | +6.0% |
| CFO | ₹-8.6 Cr | ₹6.5 Cr | ₹5.0 Cr | ₹9.5 Cr | ₹22.1 Cr | — |
| CapEx | — | — | — | — | ₹-21.9 Cr | — |
| FCF | — | — | — | — | ₹0.3 Cr | +0.0% |
| Total Assets | — | ₹90.1 Cr | ₹130 Cr | ₹148 Cr | ₹153 Cr | +14.2% |
| Total Debt | — | — | ₹14.5 Cr | ₹13.6 Cr | ₹28.2 Cr | +18.1% |
| Shareholders' Equity | — | — | ₹73.5 Cr | ₹80.8 Cr | ₹84.8 Cr | +3.7% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
BAFNAPH vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| MEDICO MEDICO REMEDIES LIMITED | -51.5% | 42 | Above Fair Value | 16.2% | — |
| MEDICAMEQ MEDICAMEQ | — | — | Pending | 3.3% | — |
| VALIANTLAB VALIANTLAB | — | — | Pending | -0.9% | — |
| ALBERTDAVD ALBERTDAVD | — | — | Pending | 4.4% | — |
| ZIMLAB ZIMLAB | — | — | Pending | 4.8% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for BAFNAPH in the last 10 years.
Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of BAFNAPH →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for BAFNAPH →
Compare
Head-to-head with peers
Compare BAFNAPH side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse BAFNAPHNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.